Best Practice & Research Clinical Rheumatology
Volume 23, Issue 6 , Pages 769-779 , December 2009

Secondary osteoporosis in patients with an osteoporotic fracture

  • C. Kok

      Affiliations

    • Kolling Institute, University of Sydney, St Leonards, Sydney 2065, Australia
    • ,
  • P.N. Sambrook

      Affiliations

    • Kolling Institute, University of Sydney, St Leonards, Sydney 2065, Australia
    • Department of Rheumatology, Royal North Shore Hospital, Building 35/Level 4, Pacific Highway, St Leonards 2065, NSW, Australia
    • Corresponding Author InformationCorresponding author. Tel.: +61 2 99267281; Fax: +61 2 99061859.

References 

  1. Sambrook PN. Glucocorticoid induced osteoporosis. In: In Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. American Society for Bone and Mineral Metabolism; 2006;p. 296–302
  2. Woolf A. An update on glucocorticoid-induced osteoporosis. Curr Opin Rheumatol. 2007;19:370–375
  3. Canalis E, Massiotti G, Giustina A, Bilsekian JP. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporosis Int. 2007;18:1319–1328
  4. Weinstein RS, Jilka RL, Parfitt AF, Manalagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. J Clin Invest. 1998;102:274–282
  5. Hofbauer L, Gori F, Riggs BL, et al. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinol. 1999;140:4382–4389
  6. Carbonare LD, Arlot ME, Chavassieux PM, et al. Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis. J Bone Miner Res. 2001;16:97–103
  7. Reid IR, Heap SW. Determinants of vertebral mineral density in patients receiving long-term glucocorticoid therapy. Arch Intern Med. 1990;150:2545–2548
  8. Sambrook PN, Kelly PJ, Keogh A, et al. Bone loss after cardiac transplantation: a prospective study. J Heart Lung Transpl. 1994;13:116–121
  9. Gough AKS, Lilley J, Eyre S, et al. Generalised bone loss in patients with early rheumatoid arthritis occurs early and relates to disease activity. Lancet. 1994;344:23–27
  10. Van Rossum EF, Lamberts SW. Polymorphisms in the glucocorticoid receptor gene and their associations with metabolic parameters and body composition. Rec Prog Horm Res. 2004;59:333–357
  11. Van Staa TP, Leufkens HGM, Abenhaim L, et al. Use of oral glucocorticoids and risk of fractures. J Bone Miner Res. 2000;15:993–1000
  12. Sambrook PN, Eisman JA, Champion GD, et al. Effect of low dose corticosteroids on bone mass in rheumatoid arthritis: a longitudinal study. Ann Rheum Dis. 1989;48:535–538
  13. Buckley LM, Leib ES, Cartularo KS, et al. Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low dose glucocorticoids in patients with rheumatoid arthritis. Ann Intern Med. 1996;125:961–968
  14. Saag K, Emkey R, Schnitzler TJ, et al. Alendronate for the prevention and treatment of glucocorticoid induced osteoporosis. New Engl J Med. 1998;339:292–299
  15. Luengo M, Picado C, Del Rio L. Vertebral fractures in steroid dependent asthma and involutional osteoporosis: a comparative study. Thorax. 1991;46:803–806
  16. Peel NFA, Moore DJ, Barrington NA, et al. Risk of vertebral fracture and relationship to bone mineral density in steroid treated rheumatoid arthritis. Ann Rheum Dis. 1995;54:801–806
  17. Van Staa TP, Laan RF, Barton IP, et al. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum. 2003;48:3224–3229
  18. Naganathan V, Jones G, Nash P, et al. Vertebral Fracture risk with long term glucocorticoids: prevalence, relationship to age, bone density and glucocorticoid use. Arch Int Med. 2000;160:2917–2922
  19. Wallach S, Cohen S, Reid DM, et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Internat. 2000;67:277–285
  20. Reid DM, Devogelare JP, Saag K, et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid induced osteoporosis: a multicentre double blind double dummy randomised controlled trial. Lancet. 2008;373:1253–1263
  21. Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid induced osteoporosis. New Engl J Med. 2007;57:2028–2039
  22. Briot K, Roux C. Drug-induced osteoporosis: beyond glucocorticoids. Curr Rheum Reports. 2008;10:102–109
  23. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005;365:60–62
  24. Coleman RE, Banks LM, Girgis SI, et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women in early breast cancer participating in the Intergroup Exemestane Study (IES): a randomized controlled study. Lancet Oncol. 2007;8:119–127
  25. Eastell R, Adams JE, Coleman RE, et al. Effects of anastazole on bone mineral density: 5 year results from the anastrozole, tamoxifen, alone or in combination trial. J Clin Oncol. 2008;26:1051–1057
  26. Brufsky A, Harker WG, Beck JT, et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol. 2007;25:829–836
  27. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;152:154–164
  28. Mittan D, Lee S, Miller E, et al. Bone loss following hypo-gonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab. 2002;87:3656–3661
  29. Diamond TH, Hiagno CS, Smith MR, et al. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer. 2004;100:892–899
  30. Michaelson MD, Kaufman DS, Lee H, et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol. 2007;25:1038–1042
  31. Vestergaard P. Epilepsy, osteoporosis and fracture risk—a meta-analysis. Acta Neurol Scand. 2005;112:277–286
  32. Omdahl JL, Morris HA, May BK. Hydroxylase enzymes of the vitamin D pathway: expression, function, and regulation. Annual Rev Nutr. 2002;22:139–166
  33. Petty SJ, Paton LM, O'Brien TJ, et al. The effect of antiepileptic medication on bone mineral measures. Neurology. 2005;65:1358–1365
  34. Souverein PC, Webb DJ, Weil JG, et al. Use of antiepileptic drugs and risk of fractures. Case–control study among patients with epilepsy. Neurology. 2006;66:1318–1324
  35. Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with use of antiepileptic drugs. Epilepsia. 2004;45:1330–1337
  36. Whooley MA, Kip KE, Cauley JA, et al. Depression, falls, and risk of fracture in older women. Study of Osteoporotic Fractures Research Group. Arch Intern Med. 1999;159:484–490
  37. Mussolino ME, Jonas BS, Looker AC. Depression and bone mineral density in young adults: results from NHANES III. Psychosom Med. 2004;66:533–537
  38. Eskandari F, Martinez PE, Torvik S, et al. Low bone mass in premenopausal women with depression. Arch Intern Med. 2007;167:2329–2336
  39. Hubbard R, Farrington P, Smith C, et al. Exposure to Tricyclic and Selective Serotonin Reupt ake Inhibitor Antidepress ants and the Risk of Hip Fr acture. Am J Epidemiol. 2003;158:77–84
  40. Hubbard R, Farrington P, Smith C, et al. Exposure to tricyclic and selective serotonin uptake inhibitor antidepressants and the risk of hip fracture. Am J Epidemiol. 2003;158:77–84
  41. Vestergaard P, Rejnmark L, Mosekilde L. Anxiolytics, sedatives, antidepressants, neuroleptics and the risk of fracture. Osteoporos Int. 2006;17:807–816
  42. Richards JB, Papaioannou A, Adachi JD, et al. Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med. 2007;167:188–194
  43. Grey A, Bolland M, Gamble G. The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab. 2007;92(4):1305–1310
  44. Schwartz AV, Sellmeyer DE, Vittinghoff E, et al. Thiazolidinedione (TZD) use and bone loss in older diabetic adults. J Clin Endocrinol Metab. 2006;91:3349–3354
  45. Short R. Fracture risk is a class effect of glitazones. BMJ. 2007;334:551
  46. Yang Y, Lewis J, Epstein S, Metz D. Long term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296:2947–2953
  47. Vestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medication and the risk of fracture. Calcif Tissue Int. 2006;79:76–83
  48. Targownick L, Lix L, Metge C, et al. Use of proton pump inhibitors and risk of osteoporosis related fractures. CMAJ. 2008;179:319–326
  49. Andreassen H, Rungby J, Dahlerup JF, Mosekilde L. Inflammatory bowel disease and osteoporosis. Scand J Gastroenterol. 1997;32(12):1247–1255
  50. Kats S. Osteoporosis in patients with inflammatory bowel disease: risk factors, prevention, and treatment. Rev Gastroenterol Dis. 2006;6(2):63–71
  51. Schulte C, Dignass AU, Mann K, Goebell H. Bone loss in patients with inflammatory bowel disease is less than expected: a follow-up study. Scand J Gastroenterol. 1999;34(7):696–702
  52. Moschen AR, Kaser A, Enrich B, et al. The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss. Gut. 2005;54(4):479–487
  53. Henderson S, Hoffman N, Prince R. A double-blind placebo-controlled study of the effects of the bisphosphonate risedronate on bone mass in patients with inflammatory bowel disease. Am J Gastroenterol. 2006;101(1):119–123
  54. Abreu MT, Geller JL, Vasiliauskas EA, et al. Treatment with infliximab is associated with increased markers of bone formation in patients with Crohn's disease. J Clin Gastroenterol. 2006;40(1):55–63
  55. Spector TD, Hall GM, McCloskey EV, Kanis JA. Risk of vertebral fracture in women with rheumatoid arthritis. Br Med J. 1993;306(6877):558
  56. Peel NFA, Moore DJ, Barrington NA, et al. Risk of vertebral fracture and relationship to bone mineral density in steroid treated rheumatoid arthritis. Ann Rheum Dis. 1995;54:801–806
  57. Orstavik RE, Haugeberg G, Uhlig T, et al. Vertebral deformities in 229 female patients with rheumatoid arthritis: associations with clinical variables and bone mineral density. Arthritis & Rheum. 2003;49(3):355–360
  58. Arai K, Hanyu T, Sugitani H, et al. Risk factors for vertebral fracture in menopausal or postmenopausal Japanese women with rheumatoid arthritis: a cross-sectional and longitudinal study. J Bone Miner Metab. 2006;24(2):118–124
  59. Reid DM, Kennedy NJS, Smith MA, et al. Total body calcium in rheumatoid arthritis: effects of disease activity and corticosteroid treatment. Br Med J. 1982;285:330–332
  60. Sambrook PN, Eisman JA, Champion GD, et al. Determinants of axial bone loss in rheumatoid arthritis. Arthritis Rheum. 1987;30:721–728
  61. Haugeberg G, Uhlig T, Falch JA, et al. Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo County Rheumatoid Arthritis register. Arthritis & Rheum. 2000;43(3):522–530
  62. Forslind K, Keller C, Svensson B, Hafstrom I. BARFOT Study Group. Reduced bone mineral density in early rheumatoid arthritis is associated with radiological joint damage at baseline and after 2 years in women. J Rheum. 2000;30(12):2590–2596
  63. Lodder MC, Haugeberg G, Lems WF, et al. Oslo-Truro-Amsterdam (OSTRA) Collaborative Study. Radiographic damage associated with low bone mineral density and vertebral deformities in rheumatoid arthritis: the Oslo-Truro-Amsterdam (OSTRA) collaborative study. Arthritis & Rheum. 2003;49(2):209–215
  64. Goldring SR, Gravallese EM. Bisphosphonates: environmental protection for the joint?. Arthritis & Rheum. 2004;50(7):2044–2047
  65. Romas E, Gillespie MT, Martin TJ. Involvement of receptor activator of NF kappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis. Bone. 2002;30(2):340–346
  66. Pettit AR, Ji H, von Stechow D, et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol. 2001;159:1689–1699
  67. Pettit AR, Walsh NC, Manning C, et al. RANKL protein is expressed at the pannus-bone interface at sites of articular bone erosion in rheumatoid arthritis. Rheumatology. 2006;45(9):1068–1076
  68. Geusens P, Vosse D, van der Heijde D, et al. High prevalence of thoracic vertebral deformities and discal wedging in ankylosing spondylitis patients with hyperkyphosis. J Rheumatol. 2001;28(8):1856–1861
  69. Speden DJ. Calin AI. Ring FJ. Bhalla AK. Bone mineral density, calcaneal ultrasound, and bone turnover markers in women with ankylosing spondylitis. J Rheum. 2002;29:516–521
  70. Lange U, Teichmann J, Strunk J, et al. Association of 1.25 vitamin D3 deficiency, disease activity and low bone mass in ankylosing spondylitis. Osteoporos Int. 2005;16(12):1999–2004
  71. Sims NA, Green JR, Glatt M, et al. Targeting osteoclasts with zoledronic acid prevents bone destruction in collagen-induced arthritis. Arthritis & Rheum. 2004;50(7):2338–2346
  72. Jarrett SJ, Conaghan PG, Sloan VS, et al. Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis. Arthritis & Rheum. 2006;54:1410–1414
  73. Cohen SB, Dore RK, Lane NE, et al. Denosumab Rheumatoid Arthritis Study Group. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum. 2008;58(5):1299–1309
  74. Zehnder Y, Luthi M, Michel D, et al. Long-term changes in bone metabolism, bone mineral density, quantitative ultrasound parameters, and fracture incidence after spinal cord injury: a cross-sectional observational study in 100 paraplegic men. Osteoporos Int. 2004;15(3):180–189
  75. Frisbie JH. Fractures after myelopathy: the risk quantified. J Spinal Cord Med. 1997;20:66–69
  76. Lazo MG, Shirazi P, Sam M, et al. Osteoporosis and risk of fracture in men with spinal cord injury. Spinal Cord. 2001;39(4):208–214
  77. Vestergaard P, Krogh K, Rejnmark L, Mosekilde L. Fracture rates and risk factors for fractures in patients with spinal cord injury. Spinal Cord. 1998;36:790–796
  78. Szollar SM, Martin EM, Sartoris DJ, et al. Bone mineral density and indexes of bone metabolism in spinal cord injury. Am J Phys Med Rehabil. 1998;77:28–35
  79. Mussolino ME, Madans JH, Gillum RF. Bone mineral density and stroke. Stroke. 2003;34(5):e20–e22
  80. Mussolino ME, Armenian HK. Low bone mineral density, coronary heart disease, and stroke mortality in men and women: the Third National Health and Nutrition Examination Survey. Annals of Epi. 2007;17(11):841–846
  81. Magnus JH, Broussard DL. Relationship between bone mineral density and myocardial infarction in US adults. Osteoporos Int. 2005;16(12):2053–2062
  82. Demirbag D, Ozdemir F, Kokino S, Berkarda S. The relationship between bone mineral density and immobilization duration in hemiplegic limbs. Ann Nucl Med. 2005;19(8):695–700
  83. Beaupre GS, Lew HL. Bone-density changes after stroke. Am J Phys Med Rehabil. 2006;85(5):464–472
  84. Runge M, Rehfeld G, Schiessl H. Skeletal adaptations in hemiplegic patients. J Musculoskelet Neuronal Interact. 2004;4(2):191–196
  85. Ramnemark A, Nyberg L, Lorentzon R, et al. Progressive hemiosteoporosis on the paretic side and increased bone mineral density in the nonparetic arm the first year after severe stroke. Osteoporos Int. 1999;9(3):269–275
  86. Offley SC, Guo TZ, Wei T, et al. Capsaicin-sensitive sensory neurons contribute to the maintenance of trabecular bone integrity. J Bone Miner Res. 2005;20(2):257–267
  87. Roberts D, Lee W, Cuneo RC, et al. Longitudinal study of bone turnover after acute spinal cord injury. J Clin Endocrinol Metab. 1998;83:415–422
  88. Maimoun L, Couret I, Mariano-Goulart D, et al. Changes in osteoprotegerin/RANKL system, bone mineral density, and bone biochemicals markers in patients with recent spinal cord injury. Calcif Tissue Int. 2005;76(6):404–411
  89. Clark JM, Jelbart M, Rischbieth H, et al. Physiological effects of lower extremity functional electrical stimulation in early spinal cord injury: lack of efficacy to prevent bone loss. Spinal Cord. 2007;45(1):78–85
  90. Eser P, de Bruin ED, Telley I, et al. Effect of electrical stimulation-induced cycling on bone mineral density in spinal cord-injured patients. Eur J Clin Invest. 2003;33(5):412–419
  91. Goktepe AS, Yilmaz B, Alaca R, et al. Bone density loss after spinal cord injury: elite paraplegic basketball players vs. paraplegic sedentary persons. Am J Phys Med Rehabil. 2004;83(4):279–283
  92. Zehnder Y, Risi S, Michel D, et al. Prevention of bone loss in paraplegics over 2 years with alendronate. J Bone Miner Res. 2004;19(7):1067–1074
  93. Turner RT, Evans GL, Lotinun S, et al. Dose-response effects of intermittent PTH on cancellous bone in hindlimb unloaded rats. J Bone Min Res. 2007;22(1):64–71

PII: S1521-6942(09)00099-0

doi: 10.1016/j.berh.2009.09.006

Best Practice & Research Clinical Rheumatology
Volume 23, Issue 6 , Pages 769-779 , December 2009

Article Tools